Expanding the potential of in vivo cell therapy with tLNP-RNAs (targeted lipid nanoparticle-RNA)
August 30, 2023
The application of lipid nanoparticles (LNPs) as a non- viral delivery system for advanced therapies, in conjunction with RNA-based medicines, is set to revolutionize the field. In this episode, David McCall, Senior Editor, BioInsights, speaks to Adrian Bot, Chief Scientific Officer and Executive Vice President of R&D, Capstan Therapeutics, about the potential of these tools to drive the burgeoning in vivo cell therapy space in particular, and the broader gene medicine field in general.
What have you have been working on lately?
What is the latest R&D progress in the in vivo CAR-T cell therapy field?
Why is lipid nanoparticle technology ideal for in vivo CAR-T cell engineering?
Advantages of lipid nanoparticles over other gene delivery platforms
Exploring the cell targeting, systemic delivery potential, and broad applicability of LNPs
What LNP learnings from the mRNA field can be leveraged for CAR-T cell engineering?
What is the most surprising thing you have learned in your preclinical work to date?
What are you most excited about in terms of Capstan's future work?
What is Capstan's biggest challenge today and how are you addressing it?
What will be Capstan's biggest challenge in five years’ time? How to prepare for it?